Financial Data and Key Metrics Changes - The company reported Q1 2024 revenue of $156 million, a 14% increase year-over-year, with clinical services revenue increasing by 17% to $135 million, driven by commercial strategy execution and increased adoption of NGS products [14][28][30] - Adjusted gross profit rose by 19% to $71 million, and adjusted EBITDA improved by 149% to a positive $3 million [15][29] - Average revenue per clinical test increased by 11% to $447, marking the third consecutive quarter of double-digit growth [31][32] Business Line Data and Key Metrics Changes - Clinical services revenue growth was primarily driven by an 11% improvement in revenue per test and a 5% increase in volume, with NGS growth exceeding 50% [30][32] - Advanced diagnostics revenue declined by 3% due to macroeconomic conditions in the pharma sector and margin optimization initiatives [33] - The company continues to focus on higher value modalities, contributing to revenue per test improvements [18][32] Market Data and Key Metrics Changes - The company noted that macro trends and operational challenges have impacted pharma revenue, but the clinical business has shown strong growth [23][24] - The NGS segment is approaching 30% of total clinical revenue, indicating a significant shift towards higher value tests [32] Company Strategy and Development Direction - The company aims to profitably grow its core clinical business, accelerate advanced diagnostics, and enhance its people and culture [17][18] - Recent leadership changes are expected to strengthen commercial synergies and drive growth, with a focus on R&D and innovation [20][22] - The company is evaluating strategic M&A opportunities, particularly in the oncology diagnostics space, as valuations are perceived to be depressed [68] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the favorable impact of the FDA's final ruling on lab-developed tests, which is expected to reduce compliance costs [6][40] - The company anticipates continued revenue growth and margin improvement, with a full-year revenue guidance of $650 million to $660 million, representing 10% to 12% growth [63][64] Other Important Information - The company ended Q1 with cash and marketable securities of $385 million, providing financial flexibility to address upcoming convertible notes maturing in May 2025 [36][37] - The ongoing litigation regarding RaDaR technology is being vigorously defended, with a jury trial scheduled for March 2025 [7][94] Q&A Session Summary Question: Insights on M&A opportunities and RaDaR litigation - Management indicated that they are exploring various pathways for M&A, including partnerships and outright acquisitions, while expressing confidence in the ongoing RaDaR litigation [44][46][68] Question: Guidance for the full year and impact of pharma business - Management reiterated that the full-year guidance remains unchanged despite a strong Q1 performance, citing challenges in the pharma business as a factor [50][72] Question: Impact of FDA LDT rule on future products - Management views the FDA ruling as favorable and believes they can manage associated costs without significant changes to their outlook [52][53] Question: Performance of the clinical business and sales force optimization - Management noted that the clinical business has shown robust growth, with ongoing efforts to optimize the sales force and improve account penetration [57][72] Question: Future of NGS and informatics offerings - Management expressed optimism about the growth potential of NGS, with plans to launch new products that will enhance their market position [87][91]

For the quarter ended March 2024, NeoGenomics (NEO) reported revenue of $156.24 million, up 13.9% over the same period last year. EPS came in at -$0.02, compared to -$0.09 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $149.82 million, representing a surprise of +4.29%. The company delivered an EPS surprise of +33.33%, with the consensus EPS estimate being -$0.03.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

NeoGenomics (NEO) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this operator of cancer-focused testing laboratories would post a loss of $0.01 per share when it actually produced earnings of $0.03, delivering a surprise of 400%.Over the last four ...

Exhibit 99.1 NeoGenomics Reports First Quarter 2024 Results First Quarter Revenue Increased 14% to $156 Million Fort Myers, Florida (April 30, 2024) - NeoGenomics, Inc. (NASDAQ: NEO) (the "Company"), a leading provider of oncology testing and global contract research services, today announced its first-quarter results for the period ended March 31, 2024. Highlights "NeoGenomics had a strong start to 2024, with first quarter revenue growth of 14% year-over-year driven by solid execution and teamwork across o ...

Wall Street expects a year-over-year increase in earnings on higher revenues when NeoGenomics (NEO) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 30. On t ...

Financial Data and Key Metrics Changes - The company reported a revenue increase of 12% year-over-year in Q4 2023, reaching $156 million, driven by growth in clinical test volume and improved revenue per test [10][27] - Adjusted gross profit increased by 17.8% year-over-year, with an adjusted gross margin of 46.7%, reflecting a 225 basis point improvement compared to Q4 2022 [8][34] - Adjusted EBITDA was positive at $9 million, marking a 900% improvement from the prior year [8][11] Business Line Data and Key Metrics Changes - Clinical Services revenue rose by 20% year-over-year to $130 million, supported by a 13% increase in revenue per test and a 6% increase in volume [4][27] - Advanced Diagnostics revenue declined by 17% year-over-year to $26 million in Q4, although it was up 5% sequentially [6][28] - The NGS (Next-Generation Sequencing) segment grew over 40% and now represents over 25% of total clinical revenue [5][28] Market Data and Key Metrics Changes - The company experienced strong growth in the community oncology market, contributing to overall revenue growth [35] - The average revenue per clinical test increased by 13% to $4.41, marking the 11th consecutive quarter of improvement [5][11] Company Strategy and Development Direction - The company aims to become the leading cancer testing information and decision support company, focusing on sustainable long-term growth [1] - Strategic priorities include profitably growing the core business, accelerating advanced diagnostics, and enhancing company culture [36] - The company is investing in digital transformation through a consolidated LIMS system to improve operational efficiency [40][92] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving a revenue growth target of 10% to 12% for 2024, with adjusted EBITDA expected to grow significantly [55][48] - The company is focused on addressing macroeconomic challenges and optimizing margins through strategic initiatives [6][28] - Management highlighted the importance of customer experience and operational efficiency as key drivers for future growth [141][143] Other Important Information - The company ended Q4 2023 with cash and marketable securities of $415 million, reflecting strong cash flow management [12][53] - The company is actively pursuing litigation related to MRD testing, emphasizing its commitment to serving cancer patients [45][129] Q&A Session All Questions and Answers Question: What is the company's strategy regarding FDA regulations and LDT? - Management indicated that they have been preparing for potential FDA rulings by enhancing their quality systems and ensuring compliance with regulatory standards [63][70] Question: Can you elaborate on the clinical volume growth expectations? - Management noted that they expect clinical volume growth to be driven by a mix of factors including NGS adoption and improved revenue cycle management [67][99] Question: How does the company plan to balance growth and profitability? - Management emphasized the importance of investing in growth initiatives while maintaining a focus on profitability, aiming for a balanced approach [85][106] Question: What are the expectations for the pharma services business? - Management sees significant growth opportunities in pharma services and informatics, with plans to expand the sales force in these areas [108][110] Question: How will the LIMS project impact operational efficiency? - The LIMS project is expected to enhance operational efficiency and productivity, leading to improved margins and turnaround times [92][94]

Financial Performance - Consolidated revenue increased by 16.1% compared to 2022, with Clinical Services revenue up 18.4% and Advanced Diagnostics Services revenue up 5.5%[240] - Total net revenue for 2023 increased by $81.9 million, or 16.1%, to $591.6 million compared to 2022[264] - Clinical Services revenue rose by $76.9 million, or 18.4%, to $495.6 million in 2023, driven by increased test volume and a favorable test mix[264] - Advanced Diagnostics revenue increased by $5.0 million, or 5.5%, to $96.0 million in 2023, primarily due to higher billings across its portfolio[265] - The net loss for the year ended December 31, 2023, was $87.968 million, a decrease from a net loss of $144.250 million in 2022, representing a 39% improvement[285] - Basic and diluted net loss per share for 2023 was $0.70, compared to $1.16 in 2022, indicating a 40% reduction in loss per share[285] - Non-GAAP Adjusted EBITDA for 2023 was $3.486 million, a significant recovery from a loss of $48.010 million in 2022[290] - The company reported a comprehensive loss of $85.743 million for 2023, compared to a comprehensive loss of $147.511 million in 2022[325] Operational Efficiency - Net cash used in operations improved by $64.0 million compared to 2022[240] - Adjusted EBITDA increased by $51.5 million to a positive $3.5 million compared to 2022[240] - Gross margin improved by 448 basis points while also enhancing turnaround time[240] - General and administrative expenses decreased by $0.3 million in 2023, representing 41.1% of revenue compared to 47.7% in 2022[271] - Research and development expenses decreased by $3.0 million in 2023, accounting for 4.6% of revenue, with expectations for future increases as new tests are developed[273][274] - Sales and marketing expenses increased by $3.5 million, or 5.2%, in 2023, primarily due to higher compensation and benefit costs[275] - Restructuring charges rose by $6.6 million, or 145.5%, in 2023, totaling $11.1 million, as part of a program to improve operational efficiency[277][279] Cash Flow and Liquidity - Cash used in operating activities decreased to $1.953 million in 2023 from $65.993 million in 2022, reflecting a $64.040 million improvement[291] - Cash provided by investing activities was $76.707 million in 2023, a substantial increase from cash used of $0.517 million in 2022[292] - Cash provided by financing activities decreased to $4.554 million in 2023 from $11.829 million in 2022, primarily due to a reduction in cash from stock issuance[293] - As of December 31, 2023, the company had $342.488 million in cash and cash equivalents, up from $263.180 million at the end of 2022[291] - The company expects sufficient liquidity to fund operational needs for at least the next 12 months, supported by cash on hand and marketable securities totaling $415.2 million[294] Investments and Growth Strategy - The company aims to expand its test offerings, including advanced NGS tools such as WES and WGS, to drive growth in Advanced Diagnostics[237] - The acquisition of Inivata provided oncology liquid biopsy technology capabilities, enhancing the company's testing services[247] - The Advanced Diagnostics segment supports pharmaceutical firms throughout the drug development process, from discovery to commercialization[248] - The company is committed to leveraging informatics and data-related tools to address real-world problems in oncology[238] - The company plans to invest in information technology and automation to reduce testing costs and improve value[239] - The company remains optimistic about growth opportunities in key markets despite potential inflationary pressures in 2024[299] Marketable Securities and Fair Value - As of December 31, 2023, the total fair value of marketable securities was $72,715,000, down from $174,809,000 as of December 31, 2022[394][395] - The Company reported a total of $55,485,000 in marketable securities with a maturity of one year or less as of December 31, 2023[396] - The Company’s Level 1 financial assets totaled $370,820,000 as of December 31, 2023[397] - The total gross unrealized losses for marketable securities as of December 31, 2023, were $1,486,000[394] Debt and Financing - The company recorded total long-term debt, net, of $538,198 thousand as of December 31, 2023, slightly increasing from $535,322 thousand in 2022[406] - The estimated fair value of the 0.25% Convertible Senior Notes due 2028 was $262.4 million as of December 31, 2023, up from $218.2 million in 2022[406] - The Company completed the sale of $201.3 million of 2025 Convertible Senior Notes with a stated interest rate of 1.25% and a maturity date of May 1, 2025, resulting in net proceeds of approximately $194.5 million after discounts and expenses[419] - The total long-term debt as of December 31, 2023, amounts to $546.25 million, with $345 million related to the 2028 Convertible Notes and $201.25 million related to the 2025 Convertible Notes[429]

Exhibit 99.1 NeoGenomics Reports Fourth Quarter and Full Year 2023 Results Fourth Quarter Revenue Increased 12% to $156 million; Full Year Revenue Increased 16% to $592 million Fort Myers, Florida, (February 20, 2024) - NeoGenomics, Inc. (Nasdaq: NEO) (the "Company"), a leading provider of oncology testing and global contract research services, today announced fourth quarter and full year 2023 results for the period ended December 31, 2023. Highlights "NeoGenomics' fourth quarter and full year 2023 results ...

ThirdQuarter 2023 Earnings Results 2 This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdictio ...

Financial Data and Key Metrics Changes - The company reported a revenue growth of 18% year-over-year, with total revenue reaching $152 million in Q3 2023 [16][33] - Adjusted EBITDA improved by 129% year-over-year to a positive $3 million, marking the fourth consecutive quarter of adjusted EBITDA growth [17][34] - Adjusted gross profit was $67 million, representing a 25% increase over the prior year, with an adjusted gross margin of 44.2%, an improvement of 247 basis points [18][36] Business Line Data and Key Metrics Changes - Clinical Services revenue increased by 20% year-over-year to $128 million, driven by a 7% increase in volume and a 12% increase in revenue per test [41] - Advanced Diagnostics revenue grew by 8% year-over-year, attributed to macroeconomic conditions and a focus on profitability, with adjusted gross profit improving by 32% [42] Market Data and Key Metrics Changes - NGS (Next-Generation Sequencing) revenue grew over 35%, now representing approximately 25% of total clinical revenue, significantly outpacing overall market growth [16][35] - The company is experiencing a shift towards higher complexity tests, contributing to improved revenue per test [33][41] Company Strategy and Development Direction - The company aims to profitably grow its core business, accelerate Advanced Diagnostics, and enhance its people and culture [21] - A key initiative includes moving to a single LIMS system to improve operational efficiencies and reduce costs, with expected benefits starting in 2024 [27][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory changes and emphasized a strong history of compliance with CAP and CLIA standards [30][31] - The company raised its revenue guidance for the year, now expecting total revenue between $585 million and $592 million, representing 15% to 16% growth [38][39] Other Important Information - The company completed three submissions to MolDX, including an additional breast application, and is focused on expanding its product offerings [19][25] - The company is actively managing cash burn, ending Q3 with cash and marketable securities of $402 million, and has improved cash flow from operations by 66% year-over-year [37] Q&A Session Summary Question: Concerns about labor inflation and cost of goods - Management acknowledged labor inflation concerns but noted that they have not seen a significant impact on hiring due to diverse labor pools in their operational regions [50][62] Question: Insights on revenue cycle management - Management highlighted that revenue cycle management is a multi-year strategy, with significant improvements expected as they focus on higher complexity tests and pricing initiatives [56][151] Question: Timeline for expanded breast MRD submission - Management expects a faster timeline for the expanded breast indication compared to previous submissions, indicating confidence in their approach [85][86] Question: Growth durability for revenue per test - Management indicated that they expect continued growth in revenue per test driven by NGS and revenue cycle management initiatives, with a multi-year opportunity ahead [111][115] Question: Market share capture for RaDaR - Management noted that the market for RaDaR is significantly underpenetrated, providing ample opportunity for growth, although they did not disclose specific market share expectations [134][135]